William Shergy, MD
Rheumatology · Huntsville, ALNPI 1073531307
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Amgen at 51.0% of the total. Reporting peaked in 2019 at $70,001 and has fallen 96.0% since, to $2,772 in 2025.
Across 1,045 payments — averaging $109.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$58K
- Bristol Myers Squibb$19K
- Janssen Scientific Affairs, LLC$16K
- AbbVie$7K
- Johnson & Johnson$7K
- Novartis$2K
- plus $6K from 29 others
Across 140 payments — averaging $2418.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$126K
- AbbVie$76K
- Gilead$65K
- Amgen$35K
- E.r. Squibb & Sons, L.L.C.$23K
- Janssen Research & Development, LLC$7K
- plus $5K from 2 others
What the payments were for
- Consulting fees$19,52817%
- Speaking & faculty fees$63,91156%
- Travel & lodging$10,1989%
- Food & beverage$20,90418%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 221 | $58,445 |
| Bristol Myers Squibb | 36 | $18,897 |
| Janssen Scientific Affairs, LLC | 20 | $15,789 |
| AbbVie | 257 | $6,641 |
| Johnson & Johnson(2 entities) | 63 | $6,528 |
| Novartis | 103 | $2,248 |
| UCB, Inc. | 91 | $1,133 |
| GSK | 49 | $1,005 |
| AstraZeneca(2 entities) | 31 | $677 |
| E.r. Squibb & Sons, L.L.C. | 44 | $643 |
| Sanofi | 7 | $529 |
| Pfizer | 42 | $500 |
| Mallinckrodt Hospital Products Inc. | 5 | $292 |
| Genentech USA, Inc. | 23 | $291 |
| Boehringer Ingelheim | 7 | $159 |
| Radius Health, Inc. | 9 | $145 |
| Regeneron Healthcare Solutions, Inc. | 8 | $121 |
| Fresenius Kabi USA, LLC | 5 | $85 |
| Lilly USA, LLC | 4 | $77 |
| Mylan Institutional Inc. | 2 | $50 |
| Mallinckrodt Enterprises LLC | 2 | $49 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 1 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Octapharma USA, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Celltrion USA Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Merck | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,605 in reported general payments places this provider in the 85th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 114 | $998,510 |
| Enbrel SureclickEtanercept | 67 | $493,316 |
| RinvoqUpadacitinib | 36 | $292,426 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $279,476 |
| StelaraUstekinumab | 12 | $260,558 |
| Xeljanz XrTofacitinib Citrate | 42 | $235,476 |
| SimponiGolimumab | 19 | $198,479 |
| OtezlaApremilast | 41 | $189,878 |
| TymlosAbaloparatide | 31 | $98,847 |
| Cosentyx Sensoready PenSecukinumab | 13 | $96,618 |
| HumiraAdalimumab | 12 | $84,056 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $79,759 |
| EnbrelEtanercept | 11 | $76,258 |
| ForteoTeriparatide | 13 | $71,833 |
| Orencia ClickjectAbatacept | 11 | $68,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Simponi | $6,528 | $459,03731 claims |
| AbbVieRinvoq, Humira | $6,641 | $376,48248 claims |
| AmgenOtezla, Enbrel | $58,445 | $266,13652 claims |
| Radius Health, Inc.Tymlos | $145 | $98,84731 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,133 | $79,75912 claims |
| Lilly USA, LLCForteo | $77 | $71,83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Huntsville
- Kun ChenHuntsville$22K
- Deepak SreeHuntsville$17K
- Ayesha JaleelHuntsville$14K
- Margaret MeehanHuntsville$13K
- Christie ThomasHuntsville$12K
- Roxanna SabghiHuntsville$11K
- Robert PhillipsHuntsville$7K
- Elijah MitchamHuntsville$5K
- Anthony TurkiewiczMountain Brk$2.2M
- Jeffrey CurtisBirmingham$612K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.